Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Treasury Shares (2022 - 2025)

SAB Biotherapeutics (SABS) has disclosed Treasury Shares for 4 consecutive years, with $5.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares changed 0.0% year-over-year to $5.5 million, compared with a TTM value of $5.5 million through Dec 2025, changed 0.0%, and an annual FY2025 reading of $5.5 million, changed 0.0% over the prior year.
  • Treasury Shares was $54665.0 for Q4 2025 at SAB Biotherapeutics, roughly flat from $54665.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $546658.0 in Q1 2022 and bottomed at -$54665.0 in Q4 2023.
  • Average Treasury Shares over 4 years is $198163.6, with a median of $54665.0 recorded in 2022.
  • Peak annual rise in Treasury Shares hit 0.0% in 2023, while the deepest fall reached 0.0% in 2023.
  • Year by year, Treasury Shares stood at $5.5 million in 2022, then changed by 0.0% to $5.5 million in 2023, then changed by 0.0% to $5.5 million in 2024, then changed by 0.0% to $5.5 million in 2025.
  • Business Quant data shows Treasury Shares for SABS at $5.5 million in Q4 2025, $5.5 million in Q3 2025, and $5.5 million in Q2 2025.